Xalatan and Meropenem drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Xalatan (latanoprost) and Meropenem (meropenem). Common drug interactions include anaemia among females and pyrexia among males.

The phase IV clinical study analyzes what interactions people have when they take Xalatan and Meropenem. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Xalatan?

Xalatan has active ingredients of latanoprost. It is often used in glaucoma. eHealthMe is studying from 25,550 Xalatan users. Check the latest studies of Xalatan.

What is Meropenem?

Meropenem has active ingredients of meropenem. eHealthMe is studying from 33,295 Meropenem users. Check the latest studies of Meropenem.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

11 people who take Xalatan and Meropenem together, and have interactions are studied.

Xalatan and Meropenem drug interactions.

What are the common drug interactions of Xalatan and Meropenem, by gender? *:

female:

Anaemia (lack of blood)
Platelet count decreased
Pyrexia (fever)
White blood cell count decreased
Anal erosion
Blood alkaline phosphatase increased
Blood creatinine increased
Blood lactate dehydrogenase increased
Blood potassium decreased
Blood pressure increased

male:

Pyrexia (fever)
Blood beta-d-glucan increased
Lymphocyte count increased
Malignant neoplasm progression (cancer tumour came back)
Non-hodgkin's lymphoma (malignant (cancer) cells form in the lymph system)
Blood potassium decreased
Diabetes insipidus (diabetes caused by a deficiency of the pituitary hormone vasopressin, which regulates kidney function)
Endophthalmitis (inflammation of the internal coats of the eye)
Neutropenia (an abnormally low number of neutrophils)
Fungal infection

What are the common drug interactions of Xalatan and Meropenem, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Pyrexia (fever)
Blood potassium decreased
Anal erosion
Blood alkaline phosphatase increased
Blood creatinine increased
Blood lactate dehydrogenase increased
Blood pressure increased
Blood urea increased
Blood uric acid increased
C-reactive protein increased

What are the existing conditions these people have? *

Sepsis (a severe blood infection that can lead to organ failure and death): 4 people, 36.36%
Febrile Neutropenia (fever with reduced white blood cells): 3 people, 27.27%
Systemic Candida (whole body fungal infection): 3 people, 27.27%
Central Nervous System Lymphoma (cancer of central nervous system forms in lymph tissue): 3 people, 27.27%
Conjunctival Disorder (conjunctival disease): 3 people, 27.27%
Tongue Coated: 2 people, 18.18%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 2 people, 18.18%
Allergies: 2 people, 18.18%
Infection: 2 people, 18.18%
Constipation: 2 people, 18.18%

* Approximation only. Some reports may have incomplete information.

Do you take Xalatan and Meropenem?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously